ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Tuesday, November 9, 2021

8:30AM-10:30AM: Abstract Number: 1746

Baricitinib Decreases Anti-dsDNA and IgG Antibodies in Adults with Systemic Lupus Erythematosus from a Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial

SLE – Treatment Poster (1732–1772)

8:30AM-10:30AM: Abstract Number: 1763

Baricitinib Reduces Proinflammatory Serum Cytokines in Patients with Systemic Lupus Erythematosus 

SLE – Treatment Poster (1732–1772)

8:30AM-10:30AM: Abstract Number: 1642

Baseline Body-mass-index and Risk for Obesity in Children with Rheumatic Disease on Moderate to High-dose Prednisone Therapy

Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)

8:30AM-10:30AM: Abstract Number: 1727

Behcet’s Disease: A Meta-analysis of Pregnancy Outcomes

Reproductive Issues in Rheumatic Disorders Poster (1711–1731)

8:30AM-10:30AM: Abstract Number: 1747

BIIB059 Demonstrates Improvement in Joint Manifestations in Participants with Systemic Lupus Erythematosus in Part a of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

SLE – Treatment Poster (1732–1772)

8:30AM-10:30AM: Abstract Number: 1885

Biological Therapy in Refractory Neurobehçet’s Disease. Multicenter Study of 42 Patients

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

8:30AM-10:30AM: Abstract Number: 1774

Blood-based Immune Profiling Combined with Machine Learning Discriminates Psoriatic Arthritis from Psoriasis Patients

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster IV: Clinical Aspects of PsA & Peripheral SpA (1773–1800)

8:30AM-10:30AM: Abstract Number: 1769

BMS-986256, an Oral Novel Toll-like Receptor 7 and 8 (TLR7/8) Inhibitor, Does Not Affect the Pharmacokinetics of Mycophenolate Mofetil in Healthy Subjects

SLE – Treatment Poster (1732–1772)

8:30AM-10:30AM: Abstract Number: 1859

Bone Mineral Density in Patients Diagnosed with Giant Cell Arteritis Taking Glucocorticoids: A Case-control Study

Systemic Sclerosis & Related Disorders – Clinical Poster III (1836–1861)

8:30AM-10:30AM: Abstract Number: 1617

Burden of Adverse Childhood Experiences in Pediatric Chronic Pain and Rheumatic Disease

Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)

8:30AM-10:30AM: Abstract Number: 1840

Can Dual-energy CT Lung Perfusion Detect Abnormalities at the Level of Lung Circulation in Systemic Sclerosis (SSc) ? Preliminary Experience in 101 Patients

Systemic Sclerosis & Related Disorders – Clinical Poster III (1836–1861)

8:30AM-10:30AM: Abstract Number: 1470

Cartilage Epigenetic Changes Induced by Microbial DNA Amplified from Human OA Samples

Osteoarthritis & Joint Biology – Basic Science Poster (1468–1479)

8:30AM-10:30AM: Abstract Number: 1565

Causal Mediation Analysis of the Relationship of Canakinumab’s Protective Effect Against Gout Flares and High-sensitivity C-reactive Protein in the CANTOS Trial

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II (1565–1583)

8:30AM-10:30AM: Abstract Number: 1479

CD14, a Toll-like Receptor Co-Factor, Influences Osteoclast Differentiation and Activity, but Does Not Alter Osteoblastic Potential of Bone-Marrow Precursors in Mice

Osteoarthritis & Joint Biology – Basic Science Poster (1468–1479)

8:30AM-10:30AM: Abstract Number: 1720

Cervical Dysplasia and HPV Infection in Women with Vasculitis

Reproductive Issues in Rheumatic Disorders Poster (1711–1731)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].